See and Strike: A Dual-Force Paradigm for Real-Time Lung Cancer Diagnosis and Non-Thermal Ablation.

Jaskiran Khosa, Roy J Cho

Abstract readReview

In one paragraph

Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jaskiran KhosaDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Section of Interventional Pulmonology, University of Minnesota, Minneapolis, MN 55455, USA.

Roy J ChoDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Section of Interventional Pulmonology, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-9952-3367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide despite advances in screening, navigational bronchoscopy, and systemic therapies. Diagnostic and therapeutic limitations persist, including uncertainty regarding intraprocedural tissue adequacy during biopsy sampling and constraints of existing ablative modalities for tumors located near critical thoracic structures. This review examines two emerging technologies: Full-Field Optical Coherence Tomography-based Dynamic Cell Imaging (DCI) and monopolar biphasic Pulsed Electric Field (PEF) ablation as complementary emerging technologies that may address these gaps. The Van Gogh™ Microscopy System (CellTivity Scientific, Inc.) utilizes DCI to enable real-time visualization of cellular metabolic activity without tissue destruction, providing functional information regarding tissue viability and microstructural morphology. The Aliya

Indexed as

bronchoscopic interventionbronchoscopic tumor ablationdynamic cell imaging (DCI)electroporationfull-field optical coherence tomography (FF-OCT)intra-procedural pathologylung cancer diagnosticsminimally invasive tumor therapynon-small cell lung cancer (NSCLC)non-thermal tumor ablationoptical imagingprecision oncologypulsed electric field (PEF) ablationreal-time tissue viability assessmentrobotic-assisted bronchoscopy

Identifiers

PMID42196919

DOI10.3390/diagnostics16101553

PMCPMC13206069

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.